



# MEDICEN PARIS REGION

---

**BioCluster for  
Innovativetherapies and  
advanced technologie in  
healthcare**



<http://www.medicen.org>



# MEDICEN PARIS REGION

---

## **THE PARIS REGION: The N°1 European Region in the field of Life Science and Health with:**

- ✓ All the big Pharma
- ✓ 50% of the French biotechnology companies (300)
- ✓ 50% of French academic research
- ✓ 9 Universities and 20 Elite schools
- ✓ 300 public and private Research laboratories
- ✓ 11,800 Researchers including 4,400 in the industry
- ✓ 5 bioparks
- ✓ N°1 European Hospital Network (AP-HP)






# THE CLUSTER'S OBJECTIVES

---

✓ To create a cluster environment fostering the development of the health sector in the Paris Region, promoting growth in its companies and jobs creation.

✓ To develop national and international partnerships to increase the cluster's members and the Paris region's capacities for international development, notoriety and attractiveness.






# MAIN R&D CAPABILITIES OF MEDICEN PARIS REGION

---

- **3 main areas**
  - ✓ **Translational medicine**
  - ✓ **Biological tools for industrial use and bio-therapeutic products**
  - ✓ **Biodigital technology: bio-computing, integration and modelling, e-health, brain-machine interface technology**
  
- **3 main areas of therapeutic and diagnostic applications**
  - ✓ **Cancers (Curie Institute, IGR...)**
  - ✓ **Neurodegenerative, sensory and psychiatric diseases**
  - ✓ **Infectious diseases (Pasteur Institute)**






# PROJETS 2005-2008

---

## 32 Private/Public projects granted


(91% of preselected projects) :

- 71,2M€ granted
- 147,8M€ total budget
  
- 233 Partners






# Non profit organization with 183 members





# MEDICEN PARIS REGION BIOPARKS

- ✓ **Genopole**  
(69 companies)
- ✓ **Biocitech**  
(24 companies)
- ✓ **Paris Biotech Santé**  
(24 companies)
- ✓ **Agoranov**  
(6 companies)
- ✓ **Biotop (Pasteur Institut)**  
(5 companies)
- ✓ **Cancer Campus**  
(planned)






# Europeannetwork Medicen / Genopole

---

- ❑ **BioCT**
- ❑ **ABC Europe:**
  - **WP1: Tools in support of internationalisation of innovativeSMEs**
  - **WP2: Cluster support services for innovativeSMEs**
  - **WP3: Transnational partneringbetween cluster organisations and businesses**
  - **WP4: IPR support for the internationalisation of innovativeSMEs**
  - **WP5: Exploitation of Joint ResearchCapability**
  - **WP6: Development of a mutual cluster ambassadorscheme**
  - **WP7: Projectsactivity support and exit strategy**
  - **WP8: Horizontal ans externalparternships**
  - **WP9: Management**







## □ Contact

- Rosalie Maurisse, PhD
- Project manager
- [rmaurisse@medicen.org](mailto:rmaurisse@medicen.org)
- Phone : 331 44 49 30 00





# Genopole : A bio cluster in the south of Paris



## Tools built since inception

- Support to establishing academic Labs
- An incubation system based on a **team** of 7 Project managers & High level **Assessments** scheme.
- A **Pre-Seed Fund** (G1J) aimed at structuring projects of Start-up Companies.
- A comprehensive system of **services** to Companies since inception.




- 
- AnimalsModels**
  - QualifiedBiobank**
  - Bioproduction**
  - Imaging facilities**



# Examples of Genopole achievements

---



- 20 research labs - 900 jobs-
- 69 biotech companies - 1 000 jobs-
- A comprehensive 83 000 m<sup>2</sup> real estate offer
- A team dedicated to development
- A system for Services and a EU Grant service
- 16 platforms and equipments
- Future Clinical & Translational Research Center in the Corbeil-Evry Hospital
- **GMP BiomanufacturingCenter opening in 2010**



# MEDICEN PARIS REGION PLUS

---

- ✓ **A unique network including top class academic laboratories and high tech partners companies**
- ✓ **On going programs to improve companies environment (manpower, capital fundings, international relations...)**
- ✓ **Access to fundings for :**
  - **collaborative R&D projects**
  - **collaborative technical platforms**
- ✓ **Close to regulatory bodies**
- ✓ **A door to the EU and US markets**

